Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | ATR | Q13535 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PTAFR | P25105 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956040 | 0.97 | KMT2A (0.52) | IRAK4KMT2APOLBATRMAPT | |
| Hydrochloric Acid SCHEMBL2947061 | 0.96 | KMT2A (0.51) | IRAK4KMT2APOLBATRMAPT | |
| Oxalic Acid SCHEMBL2954733 | 0.94 | IRAK4 (0.49) | IRAK4KMT2APOLBATRMAPT | |
| SCHEMBL2952870 | 0.94 | IRAK4 (0.48) | IRAK4KMT2APOLBATRMAPT | |
| SCHEMBL2953230 | 0.88 | KMT2A (0.59) | IRAK4KMT2APOLBATRMAPT | |
| SCHEMBL2947104 | 0.86 | IRAK4 (0.48) | IRAK4KMT2APOLBATRMAPT | |
| SCHEMBL2954540 | 0.86 | KMT2A (0.50) | KMT2APOLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL3025810 | 0.84 | NPC1 (0.54) | KMT2APOLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL2951651 | 0.84 | NPC1 (0.54) | KMT2APOLBMAPTLMNASMN1; SMN2 | |
| SCHEMBL2950504 | 0.82 | MEN1 (0.50) | KMT2APOLBMAPTLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759350-B2 | Pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-20 | — | — | US | claimed |
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | claimed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | claimed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | claimed |
| US-7759350-B2 | Pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2010-07-20 | — | — | US | disclosed |
| EP-1931642-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | Orchid Research Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| US-20070072876-A1 | Novel pyrimidine carboxamides | ORCHID RESEARCH LABORATORIES LTD. (IN) | 2007-03-29 | — | — | US | disclosed |
| WO-2007031829-A2 | NOVEL PYRIMIDINE CARBOXAMIDES | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072876-A1 | Novel pyrimidine carboxamides | UACA, SI, MYLK2 | IRAK4 292/4885KMT2A 4280/4885POLB 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.